BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stadler D, Kächele M, Jones AN, Hess J, Urban C, Schneider J, Xia Y, Oswald A, Nebioglu F, Bester R, Lasitschka F, Ringelhan M, Ko C, Chou WM, Geerlof A, van de Klundert MA, Wettengel JM, Schirmacher P, Heikenwälder M, Schreiner S, Bartenschlager R, Pichlmair A, Sattler M, Unger K, Protzer U. Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Rep 2021;22:e49568. [PMID: 33969602 DOI: 10.15252/embr.201949568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Akbar SMF, Al Mahtab M, Cesar Aguilar J, Uddin MH, Khan MSI, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical. Exploration of Medicine. [DOI: 10.37349/emed.2021.00058] [Reference Citation Analysis]
2 Oswald A, Chakraborty A, Ni Y, Wettengel JM, Urban S, Protzer U. Concentration of Na+-taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus. Sci Rep 2021;11:19799. [PMID: 34611272 DOI: 10.1038/s41598-021-99263-3] [Reference Citation Analysis]
3 Brezgin S, Kostyusheva A, Bayurova E, Volchkova E, Gegechkori V, Gordeychuk I, Glebe D, Kostyushev D, Chulanov V. Immunity and Viral Infections: Modulating Antiviral Response via CRISPR-Cas Systems. Viruses 2021;13:1373. [PMID: 34372578 DOI: 10.3390/v13071373] [Reference Citation Analysis]
4 Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Reference Citation Analysis]
5 Stadler D, Kächele M, Jones AN, Hess J, Urban C, Schneider J, Xia Y, Oswald A, Nebioglu F, Bester R, Lasitschka F, Ringelhan M, Ko C, Chou WM, Geerlof A, van de Klundert MA, Wettengel JM, Schirmacher P, Heikenwälder M, Schreiner S, Bartenschlager R, Pichlmair A, Sattler M, Unger K, Protzer U. Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20. EMBO Rep 2021;22:e49568. [PMID: 33969602 DOI: 10.15252/embr.201949568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee AR, Park YK, Dezhbord M, Kim K. Interaction between the Hepatitis B Virus and Cellular FLIP Variants in Viral Replication and the Innate Immune System. Viruses 2022;14:373. [DOI: 10.3390/v14020373] [Reference Citation Analysis]
7 Kitamura K, Fukano K, Que L, Li Y, Wakae K, Muramatsu M. Activities of endogenous APOBEC3s and uracil-DNA-glycosylase affect the hypermutation frequency of hepatitis B virus cccDNA. J Gen Virol 2022;103. [PMID: 35438620 DOI: 10.1099/jgv.0.001732] [Reference Citation Analysis]
8 Kostyushev D, Kostyusheva A, Ponomareva N, Brezgin S, Chulanov V. CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers. Nucleic Acid Ther 2021. [PMID: 34797701 DOI: 10.1089/nat.2021.0075] [Reference Citation Analysis]